PDF DatasheetHuman, Mouse, Rat, Cat, and Pig Anti-Myogenin Antibody Product Attributes
Species: Human, Mouse, Rat, Cat, and Pig
Tested Applications: Flow Cytometry, Immunofluorescence, Immunohistochemistry (IHC).
Application Notes: Flow Cytometry (0.5-1ug of antibody/million cells in 0.1ml), Immunofluorescence (0.5-1ug of antibody/ml), Immunohistochemistry (IHC) (Formalin-fixed) (0.5-1.0ug of antibody/ml for 30 minutes at RT)
Clonality: Monoclonal
Anti-Myogenin Antibody Clone: MGN185 + F5D
Clone MGN185 + F5D Host and Isotype: Mouse IgG
Anti-Human, Mouse, Rat, Cat, and Pig Myogenin Positive Control Sample: Rh-30 cells. Skeletal muscle or rhabdomyosarcoma.
Cellular Localization of Antibody Nuclear
Buffer and Stabilizer: 10mM PBS with 0.05% BSA & 0.05% azide.
Antibody Concentration: 200ug/ml
Antibody Purification Method:Protein A/G Purified
Immunogen: Human myogenin recombinant protein (MGN185); Rat myogenin recombinant fragment containing amino acid 30-224 (F5D)
Storage Conditions: Store at 2 to 8° C (refrigerate). Stable for 24 months when properly stored.
Myogenin Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-MYOG antibody staining is expected to be primarily localized to the nucleoplasm. There is variability in either the signal strength or the localization of signal in nucleoplasm from cell to cell.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Myogenin expression as measured by anti-Myogenin antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | + | + | – | – | – | + | + | + | – | + | + | ++ | – | + | + | – | – | + | – | – |
| MYOG Variability | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ | ++ | +++ | ++ | ++ | ++ | ++ | ++ |
| Myogenin General Information | |
|---|---|
| Alternate Names | |
| Myogenin, myogenic factor 4, MYOG | |
| Molecular Weight | |
| 34kDa | |
| Chromosomal Location | |
| 1q32.1 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | MYOG |
| Entrez Gene ID | 4656 |
| Ensemble Gene ID | ENSG00000122180 |
| RefSeq Protein Accession(s) | NP_002470 |
| RefSeq mRNA Accession(s) | NM_002479 |
| RefSeq Genomic Accession(s) | NC_000001, NC_018912 |
| UniProt ID(s) | P15173 |
| UniGene ID(s) | P15173 |
| HGNC ID(s) | 7612 |
| Cosmic ID(s) | MYOG |
| KEGG Gene ID(s) | hsa:4656 |
| PharmGKB ID(s) | PA31417 |
| General Description of Myogenin. | |
| Myogenin is a member of the MyoD family of myogenic basic helix-loop-helix (bHLH) transcription factors that also includes MyoD, Myf-5,, MRF4 (also known as herculinor Myf-6). MyoD family members are expressed exclusively in skeletal muscle, play a key role in activating myogenesis by binding to enhancer sequences of muscle-specific genes. The regulatory domain of MyoD is approximately 70 amino acids in length, includes both a basic DNA binding motif, a bHLH dimerization motif. MyoD family members share about 80% amino acid homology in their bHLH motifs. Anti-myogenin labels the nuclei of myoblasts in developing muscle tissue,, is expressed in tumor cell nuclei of rhabdomyosarcoma, some leiomyosarcomas. Positive nuclear staining may occur in Wilms tumor. | |
Limitations and Warranty
enQuire Bio’s Myogenin Anti-Human Monoclonal is available for Research Use Only. This antibody is guaranteed to work for a period of two years when properly stored.
There are no reviews yet.